Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 24, 2026

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Selective lymph node dissection for castration-resistant prostate cancer.

Jonas Busch1, Stefan Hinz, Carsten Kempkensteffen

  • 1Department of Urology, Charité University Medicine Berlin, Berlin, Germany.

Urologia Internationalis
|March 9, 2012
PubMed
Summary

Retroperitoneal lymph node dissection (LND) is a safe procedure for castration-resistant prostate cancer patients with lymph node metastases. This surgical approach may improve prostate-specific antigen (PSA) levels and delay the need for systemic therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer.

Prostate cancer and prostatic diseases·2025
Same author

Effects of a Patient Decision Aid for Nonmetastatic Prostate Cancer Established in Routine Care: The Randomized Controlled EvEnt-PCA Trial.

European urology focus·2025
Same author

Economics, Ergonomics, Effectiveness: A Monocentric Comparison of Single-Use vs. Reusable Flexible Ureteroscopes in Challenging Kidney Stone Cases.

Aktuelle Urologie·2025
Same author

KDM6A expression loss is frequent in low grade non-invasive urothelial carcinomas of the urinary bladder.

Pathologica·2025
Same author

Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy.

The oncologist·2024

Area of Science:

  • Urology
  • Oncology
  • Surgical Oncology

Background:

  • Limited data exists on the clinical outcomes of retroperitoneal lymph node dissection (LND) in castration-resistant prostate cancer (CRPC) patients.
  • Metastatic CRPC poses significant challenges in treatment selection and management.

Purpose of the Study:

  • To evaluate the safety and efficacy of retroperitoneal lymph node dissection (LND) in patients with castration-resistant prostate cancer (CRPC) and lymph node metastases.
  • To assess the impact of LND on prostate-specific antigen (PSA) levels and clinical outcomes.

Main Methods:

  • Retrospective analysis of 6 CRPC patients who underwent retroperitoneal LND between 2005 and 2010.
  • Evaluation of complication rates, prostate-specific antigen (PSA) kinetics, and survival outcomes post-LND.

Related Experiment Videos

Last Updated: May 24, 2026

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Main Results:

  • No intra- or postoperative complications were observed in the 6 patients.
  • An average postoperative PSA decline of 39.3% was noted.
  • Median bone metastasis-free survival was 15.5 months, and median overall survival was 31.7 months.

Conclusions:

  • Selective retroperitoneal lymph node dissection (LND) can be safely performed in castration-resistant prostate cancer (CRPC) patients.
  • LND demonstrated a positive effect on PSA levels and kinetics for most patients.
  • This approach may serve as an alternative palliative treatment, potentially delaying systemic therapy by up to 12 months.